BMRA: Biomerica, Inc. Stock

SIC 2835 – In Vitro and In Vivo Diagnostic Substances

Valuation
Market Cap ($M) 8.80
Enterprise Value ($M) 5.75
Book Value ($M) 5.53
Book Value / Share 0.30
Price / Book 1.59
NCAV ($M) 4.36
NCAV / Share 0.24
Price / NCAV 2.02

Profitability (mra)
Return on Invested Capital (ROIC) -0.80
Return on Assets (ROA) -0.47
Return on Equity (ROE) -0.62

Liquidity (mrq)
Quick Ratio 2.76
Current Ratio 3.76

Balance Sheet (mrq) ($M)
Current Assets 6.20
Assets 7.38
Liabilities 1.84
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-11 13G Wasatch Advisors Inc 0.00
11-14 13G/A Granahan Investment Management Inc/ma 3.14 -51.28

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED FEBRUARY 28, 2025 or ☐ TRANSITION REPORT PURSUA
2025-01-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUA
2024-10-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2024 or ☐ TRANSITION REPORT PURSUANT
2024-08-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For The Fiscal Year Ended May 31, 2024 or ☐ Transition Report Pursuant to Section

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 284,933 687,836 41.42
2025-04-16 277,185 634,674 43.67
2025-04-15 32,636 80,510 40.54
2025-04-14 21,467 63,450 33.83

(click for more detail)

Similar Companies
BFRI – Biofrontera Inc. BGM – BGM Group Ltd.
BIVI – BioVie Inc. BNTC – Benitec Biopharma Inc.
BOLT – Bolt Biotherapeutics, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.